Full Press Release Details
Therapeutics Appoints Marc Lustig to its Board of Directors
Calif. and VANCOUVER, British Columbia, September 1, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) ("BriaCell"
or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast
cancer, announces the appointment of Mr. Marc Lustig to the Company's Board of Directors, effective September 1, 2021. Marc, through
his investment company L5 Capital Inc., owns 1,530,000 common shares of BriaCell, representing 10.0% of BriaCell's issued and outstanding
is our pleasure to welcome Marc to our Board of Directors at this transformative phase for BriaCell," remarked Jamieson Bondarenko,
BriaCell's Chairman of the Board. "Marc's exemplary expertise in both corporate finance and the pharmaceutical industry
will be invaluable to our capital markets and corporate partnership strategies as we advance our novel cancer therapeutics."
novel technology has the potential to change the way we treat cancer," said Marc Lustig. "As the largest shareholder and
now a director, I have been thoroughly impressed by the BriaCell team's passion and commitment to bring new treatment options to
cancer patients who do not respond to current therapies. I look forward to working with the team on their strategic capital and partnering
activities to drive significant value for shareholders."
Lustig is a highly regarded investor, entrepreneur, and corporate finance veteran with a deep understanding of the life sciences industry,
including biotechnology and pharmaceuticals, as well as the legal cannabis industry. Marc holds MSc and MBA degrees from McGill University
and his professional experience includes working at Merck & Co., and his capital markets career includes roles in biotech equity
research, corporate finance and as Head of Capital Markets. Mr. Lustig was the founder and CEO of Origin House which was sold to Cresco
Labs Inc. (CSE: CL; OTCQX: CRLBF) in 2020 where he currently serves as a director. In addition to being a director of a number of public
companies, Marc founded the Lustig Family Medical Cannabis Research & Care Fund of the Cedars Cancer Foundation that provides cannabis
to palliative cancer patients.
the Company announces that its Board of Directors has approved a grant of options for 100,000 common shares (the "Options")
to Mr. Lustig in his role as a director of the Company, pursuant to the Company's stock option plan. The Options have an exercise
price of C$7.24 per share, a term of five years, and vest immediately. Mr. Lustig intends to donate any proceeds from the exercise of
such Options to the Cedars Cancer Foundation. The grant of the Options is subject to the approval of the TSX Venture Exchange.
BriaCell Therapeutics Corp.
is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information
is available at https://briacell.com/.
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions
as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading
"Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under "Risks
and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities
and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty
to update such information except as required under applicable law.
TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.